CN1110313C - A set of medicine for prevention and curing of cholesthiasis disease and plan for discriminating choleithiasis kind - Google Patents
A set of medicine for prevention and curing of cholesthiasis disease and plan for discriminating choleithiasis kind Download PDFInfo
- Publication number
- CN1110313C CN1110313C CN98104574A CN98104574A CN1110313C CN 1110313 C CN1110313 C CN 1110313C CN 98104574 A CN98104574 A CN 98104574A CN 98104574 A CN98104574 A CN 98104574A CN 1110313 C CN1110313 C CN 1110313C
- Authority
- CN
- China
- Prior art keywords
- medicine
- cholelithiasis
- parts
- calculus
- applicable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 230000002265 prevention Effects 0.000 title abstract description 4
- 201000010099 disease Diseases 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 2
- 201000001883 cholelithiasis Diseases 0.000 claims abstract description 52
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 14
- 239000003292 glue Substances 0.000 claims description 12
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 12
- 210000003038 endothelium Anatomy 0.000 claims description 11
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 10
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 10
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 10
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 9
- 229940093265 berberine Drugs 0.000 claims description 9
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 9
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 8
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 8
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 8
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 8
- 229940025878 hesperidin Drugs 0.000 claims description 8
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 8
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 8
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 7
- 235000001510 limonene Nutrition 0.000 claims description 7
- 235000019165 vitamin E Nutrition 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- 239000011709 vitamin E Substances 0.000 claims description 7
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- 229940087305 limonene Drugs 0.000 claims description 6
- 235000020778 linoleic acid Nutrition 0.000 claims description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 6
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 5
- 229960003321 baicalin Drugs 0.000 claims description 5
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 5
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 5
- 235000019158 vitamin B6 Nutrition 0.000 claims description 5
- 239000011726 vitamin B6 Substances 0.000 claims description 5
- 229940011671 vitamin b6 Drugs 0.000 claims description 5
- 241001597008 Nomeidae Species 0.000 claims description 4
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 241000207929 Scutellaria Species 0.000 claims description 2
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 claims description 2
- 229940031016 ethyl linoleate Drugs 0.000 claims description 2
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 6
- 150000002628 limonene derivativess Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000002980 postoperative effect Effects 0.000 abstract description 4
- 206010008617 Cholecystitis chronic Diseases 0.000 abstract description 3
- 201000001352 cholecystitis Diseases 0.000 abstract description 3
- 208000011580 syndromic disease Diseases 0.000 abstract description 3
- 208000015163 Biliary Tract disease Diseases 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract description 2
- 208000004845 Cholecystolithiasis Diseases 0.000 abstract 1
- 230000001133 acceleration Effects 0.000 abstract 1
- 210000002603 extrahepatic bile duct Anatomy 0.000 abstract 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 239000002904 solvent Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000004575 stone Substances 0.000 description 7
- 210000000941 bile Anatomy 0.000 description 4
- 238000005336 cracking Methods 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010004637 Bile duct stone Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000003591 anti-choleraic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000000387 litholytic effect Effects 0.000 description 1
- 238000002504 lithotomy Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HVHKMUMXERBUAN-IFADSCNNSA-N mesobilirubin IXalpha Chemical compound N1C(=O)C(CC)=C(C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C)C(=O)N\3)CC)N2)CCC(O)=O)N1 HVHKMUMXERBUAN-IFADSCNNSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000018192 pine bark supplement Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 229940106796 pycnogenol Drugs 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000008812 xiaoyanlidan Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a set of medicine for preventing and curing biliary tract diseases of chronic cholecystitis, intra-and extrahepatic bile duct calculus, cholecystolithiasis, biliary postoperative residual calculus, gallbladder-heart syndrome, etc. The medicine has different megascopic calculus dissolving functions to more than 90% of biliary calculus, and has broad-spectrum calculus dissolving and preventing function and the ratio of curative effect and price which are obviously superior to those of the known medicine until now. The present invention has the new purpose of calculus kind identification so that the abuses of calculus forming acceleration, etc. caused by blind medication by patients are avoided. The present invention is novel special calculus dissolving and preventing medicine which combines the three methods of dissolution, removal and prevention into a whole.
Description
We apply for one group of medicine and application that prevents and treats cholelithiasis to State Patent Office the present, and purpose is to make this part invention achievement obtain complete patent protection comprehensively.
Show at present according to statistics both at home and abroad, after liver and bile stone disease (abbreviation cholelithiasis) patient implements lithotomy, in 3 years the recurrence of hepatolithiasis rate up to 30%～50%, after 5 years then up to more than 60%.And we find when 365 routine cholelithiasiss recurrence patients are followed up a case by regular visits to, the patient 64% or more since the postoperative selection prevent that the stone medicine is improper and cause.Trace it to its cause, mainly be because clinicist and patient can not correctly discern choleithiasis kind, and existing market is sold the medicine of control cholelithiasis, what have has only the anti-inflammatory and choleretic effect, what have can only the dissolving cholesterol calculus, and exist side effect many, cost an arm and a leg, make defectives such as most of patients is difficult to bear.Event is clinical to be difficult to accomplish rational use of drug, thereby is seriously restricting clinical molten anti-stone curative effect.This pharmaceutical composition just is being based on the above-mentioned difficult problem of solution and is inventing.It had both had the molten anti-masonry usefulness of significant wide spectrum, had possessed the new purposes of differentiating choleithiasis kind simultaneously again, had avoided quickening many drawbacks such as cholelithiasis formation on the contrary because of the blindness medication.
Specifically, the present invention relates to the medicine of one group of treatment and biliary tract diseases such as prevention chronic cholecystitis, liver inside and outside bile duct stone, cholelithiasis, biliary postoperative residual calculus and gallbladder heart syndrome.Its prescription derives from traditional Chinese medical science secret recipe, again by clinical verification for many years, carries out the science screening in conjunction with modern pharmacology and forms.It meets rules such as traditional Chinese medical science depressed liver-energy dispersing and function of gallbladder promoting, clearing away heat-damp and promoting diuresis, nourishing yin and activating blood, hard masses softening and resolving, makes catharsis functional rehabilitation, bile secretion and the drainage of liver normal, thereby plays the effect of lithodialysis, calculus, anti-stone.Its component and proportion relation are preferably: 1～10 part of unsaturated fatty acid, 0.004～0.15 part of antioxidant, phosphatidase 10 .05～3 part, natural glue or 1～50 part of medicinal resin, 1～25 part of Endothelium corneum, 1～30 part of Pericarpium Citri Reticulatae, 1～35 part on Pericarpium Citri Reticulatae Viride, 1～50 part of Radix Scutellariae, 1～30 part of Rhizoma Coptidis; Be preferably: 1.5～8 parts of unsaturated fatty acids, 0.005～0.1 part of antioxidant, phosphatidase 10 .1～2.5 part, 2～40 parts of natural glue or medicinal resins, 4～20 parts of Endothelium corneum, 0.1～3 part of 2～25 parts of Pericarpium Citri Reticulataes or hesperidin, 0.2～3 part of 2～30 parts on Pericarpium Citri Reticulatae Viride or limonene, 0.2～5 part of 3～40 parts of Radix Scutellariaes or baicalin or baicaligenin, 0.1～5 part of 2～25 parts of Rhizoma Coptidis or berberine, add a small amount of synergist, through sterilization, modern crafts such as pulverizing and extraction are refining to form, but also unsaturated fatty acid and derivant thereof can contained, on the bases such as antioxidant, select suitable medicine and proportioning according to different types of cholelithiasis.
More detailed saying, the unsaturated fatty acid of indication comprises in the component: consistent lubricant acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, linoleic acid, EPA (eicosapentaenoic acid) and DHA (docosahexenoic acid) or the like are first-selection with linoleic acid and derivant thereof wherein.Antioxidant can be selected vitamin E and Natural antioxidant pycnogenol for use.Phospholipid will be handled through the past sterin.In common knowledge as everybody, phospholipid had both belonged to unsaturated fatty acid, belonged to the oiliness antioxidant again.Natural glue can utilize natural drug such as Carapax Trionycis to make, and selects medicinal resin or resin bead to replace natural glue that better curative effect is also arranged certainly.Endothelium corneum is chicken, duck, Endothelium corneum Anseris domestica, wherein is first-selected with the Endothelium corneum Anseris domestica.From natural drugs such as Pericarpium Citri Reticulatae, Pericarpium Citri Reticulatae Viride, Radix Scutellariae, Rhizoma Coptidis, can extract plurality of active ingredients, as hesperidin, limonene, baicalin or baicaligenin, berberine etc.The synergist master who is said in the prescription refers to nicotinic acid, inositol, vitamin C, vitamin B6 etc.
In addition, we find in experiment, said composition can significantly increase the excretion of bile mesobilirubin, and the combining of bilirubin and said composition, played solubilising cholelithiasis effect in the unexpected body, this may be that bilirubin has been brought into play especially effectively antioxidation, has stably prevented the loss prematurely in vivo of linoleic acid and other unsaturated fatty acid, thereby the ability of its transformed cholesterol is significantly strengthened.The characteristic of the anti-stone of the beat all calculus dissolving and excreting that said composition had also shows its summation that is higher than in the compositions the independent or curative effect of addition of every kind of composition own evident in efficacy, has played separately or the molten anti-masonry usefulness of wide spectrum that addition itself is not had.
We carry out the experiment of external lithodialysis to 240 routine cholelithiasiss at random, and the result shows, said composition has in various degree naked eyes observability litholytic effect to the cholelithiasis more than 90%.We get the postoperative patient of stone by the cholelithiasis and the 544 routine percutaneous gallbladder mirrors that 852 examples are met Chinese bureau of drug administration new drug (Chinese medicine) in 1989 clinical research guideline, adopt continuously or be interrupted and alternately take 1～4 course of treatment of said composition (the per half a year course of treatment), carry out clinical verification, confirm through the front and back ultrasound diagnosis, treatment cholelithiasis and chronic cholecystitis total effective rate are respectively 93.7% and 96%, treatment gallbladder heart syndrome total effective rate is 92.4%, the recurrence of prevention liver and bile stone, the recurrence of hepatolithiasis rate is controlled in 10% in 5 years.Its curative effect all is higher than medicine matched groups such as taking XIAOYAN LIDAN PIAN, DANTONG, and the zoopery result is similar to clinical verification.The molten anti-masonry of the wide spectrum that this pharmaceutical composition had is used and curative effect price ratio in sum, significantly is better than known drug so far.
Differentiate the choleithiasis kind technical scheme, its technical characterictic comprises step and environmental condition.Its key step comprises: it is an amount of to get the cholelithiasis solvent, and cholelithiasis is put into solvent, is advisable so that cholelithiasis is soaked fully.Leave standstill or jolting every day solvent (or boiling) 10 hours in, ambient temperature is controlled between-5 ℃ to 150 ℃, pressure is controlled at-1KPa to 15KPa between.According to the color of cholelithiasis with whether dissolve or cracking, and the time that dissolving or cracking took place, illustrate molten anti-masonry with and differentiate choleithiasis kind.Its material property is: the cholelithiasis solvent.
This pharmaceutical composition collected in the small container (also can directly select the cholelithiasis solvent for use), placed one day, it is an amount of to get its clarification medicinal liquid, again cholelithiasis is put into medicinal liquid, is advisable so that cholelithiasis is soaked fully.Every day shake the medicinal liquid 3～30 minutes that cholelithiasis is housed, in medicinal liquid, do not stop to roll to be advisable with cholelithiasis thereafter.Environmental condition is: temperature-5 ℃～150 ℃, pressure-1KPa～15KPa.The program of differentiating cholelithiasis is as follows: the cholelithiasis outward appearance be white to light lark, as above interior cholelithiasis has and dissolution phenomena such as dwindles 1 week of scheme, is cholesterol and Combination cholelithiasis thereof; The cholelithiasis outward appearance is faint yellow to brownish black, and cholelithiasis has the cracking phenomenon in 5 days, is bilirubin and Combination cholelithiasis thereof; The cholelithiasis outward appearance is white to brownish black, and no cholelithiasis dissolves or the cracking phenomenon in 1 week, and being calcic is main Combination cholelithiasis.Such scheme also can be by changing cholelithiasis solvent and environmental condition such as temperature and pressure, leave standstill or prolong the time of at every turn shaking solvent, reduce or increase the intensity of shaking solvent, the time that Mi Yanchang or shortening lithodialysis phenomenon are taken place, can differentiate choleithiasis kind equally with this.
Embodiment:
(example one) following medicine is formed and proportion relation mainly is applicable to control cholesterol and Combination cholelithiasis thereof, but also is applicable to other kind cholelithiasis: linoleic acid 10g, vitamin E 0.05g, phosphatidase 10 .7g, natural glue 40g, Endothelium corneum 10g, hesperidin 0.3g, limonene 1g, berberine 0.2g.
(example two) following medicine is formed and proportion relation mainly is applicable to control bilirubin and Combination cholelithiasis thereof, also is applicable to other kind cholelithiasis: Ethyl linoleate 9g, vitamin E 0.06g, natural glue 20g, Endothelium corneum 20g, hesperidin 0.2g, baicalin 4g, berberine 4g nicotinic acid 0.75g, vitamin B6 0.15g.
(example three) following medicine is formed and proportion relation is applicable to that mainly the control calcic is main Combination cholelithiasis, also is applicable to other kind cholelithiasis: linoleic acid 10g, vitamin E 0.1g, phosphatidase 12 g, medicinal resin or natural glue 10g, hesperidin 2.5g, limonene 0.4g, baicalin or baicaligenin 1.5g, berberine 1g, vitamin B6 0.06g.
But also can contain on unsaturated fatty acid and the bases such as derivant, antioxidant thereof, select suitable medicine and proportioning according to different types of cholelithiasis.
Claims (6)
1. medicine of preventing and treating cholelithiasis, it is characterized in that it can be on the basis of containing unsaturated fatty acid and derivant thereof, antioxidant, select suitable raw material and proportioning according to different types of cholelithiasis, it is made by the following weight proportion raw material: 1～10 part of unsaturated fatty acid, 0.004～0.15 part of antioxidant, phosphatidase 10 .05～3 part, 1～50 part of natural glue, 1～25 part of Endothelium corneum, 1～30 part of Pericarpium Citri Reticulatae, 1～35 part on Pericarpium Citri Reticulatae Viride, 1～50 part of Radix Scutellariae, 1～30 part of Rhizoma Coptidis.
2. the medicine of control cholelithiasis according to claim 1, wherein the weight proportion of each raw material is: 1.5～8 parts of unsaturated fatty acids, 0.005～0.1 part of antioxidant, phosphatidase 10 .1～2.5 part, 2～40 parts of natural glues, 4～20 parts of Endothelium corneum, 2～25 parts of Pericarpium Citri Reticulataes, 2～30 parts on Pericarpium Citri Reticulatae Viride, 3～40 parts of Radix Scutellariaes, 2～25 parts of Rhizoma Coptidis.
3. the medicine of control cholelithiasis according to claim 2, it is characterized in that: wherein 0.1～3 part of replacement of 2～25 parts of available hesperidins of Pericarpium Citri Reticulatae, 0.2～3 part of replacement of 2～30 parts of available limonenes of Pericarpium Citri Reticulatae Viride, 3～40 parts of available baicalins of Radix Scutellariae or 0.2～5 part of replacement of baicaligenin, 0.1～5 part of replacement of 2～25 parts of available berberine of Rhizoma Coptidis.
4. one kind mainly is applicable to control cholesterol and Combination cholelithiasis thereof, but also be applicable to the medicine of other kind cholelithiasiss, it is characterized in that it is made up of the following weight proportion raw material: linoleic acid 10g, vitamin E 0.05g, phosphatidase 10 .7g, natural glue 40g, Endothelium corneum 10g, hesperidin 0.3g, limonene 1g, berberine 0.2g.
5. one kind mainly is applicable to control bilirubin and Combination cholelithiasis thereof, but also be applicable to the medicine of other kind cholelithiasiss, it is characterized in that forming: Ethyl linoleate 9g, vitamin E 0.06g, natural glue 20g, Endothelium corneum 20g, hesperidin 0.2g, baicalin 4g, berberine 4g, nicotinic acid 0.75g, vitamin B6 0.15g by the following weight proportion raw material.
6. one kind is applicable to that mainly the control calcic is main Combination cholelithiasis, but also be applicable to the medicine of other kind cholelithiasiss, it is characterized in that forming: linoleic acid 10g, vitamin E 0.1g, phosphatidase 12 g, natural glue 10g, hesperidin 2.5g, limonene 0.4g, baicaligenin 1.5g, berberine 1g, vitamin B6 0.06g by the following weight proportion raw material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98104574A CN1110313C (en) | 1998-03-18 | 1998-03-18 | A set of medicine for prevention and curing of cholesthiasis disease and plan for discriminating choleithiasis kind |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98104574A CN1110313C (en) | 1998-03-18 | 1998-03-18 | A set of medicine for prevention and curing of cholesthiasis disease and plan for discriminating choleithiasis kind |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011251883A Division CN1184478C (en) | 1998-03-18 | 1998-03-18 | Gallstone kind identifying method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1228969A CN1228969A (en) | 1999-09-22 |
| CN1110313C true CN1110313C (en) | 2003-06-04 |
Family
ID=5218301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98104574A Expired - Fee Related CN1110313C (en) | 1998-03-18 | 1998-03-18 | A set of medicine for prevention and curing of cholesthiasis disease and plan for discriminating choleithiasis kind |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1110313C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009060452A2 (en) * | 2007-11-08 | 2009-05-14 | Galmed International Ltd. | Methods and compositions for treating biliary cholesterol crystallization and related conditions |
| CN102895462B (en) * | 2012-09-27 | 2014-03-12 | 林一帆 | Traditional Chinese medicine for preventing and treating gallstone relapse |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1127128A (en) * | 1995-09-14 | 1996-07-24 | 隋嫣玲 | Traditional Chinese medicine for cholelithiasis and preparing method |
-
1998
- 1998-03-18 CN CN98104574A patent/CN1110313C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1127128A (en) * | 1995-09-14 | 1996-07-24 | 隋嫣玲 | Traditional Chinese medicine for cholelithiasis and preparing method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1228969A (en) | 1999-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100804480B1 (en) | Memory enhancing composition | |
| JP2002527389A (en) | Combination of carnitine and resveratrol for prevention or treatment of cerebral and age-related diseases | |
| KR102121153B1 (en) | Dietary herbal composition, dietary herbal medicine pill comprising the same and method for manufacturing thereof | |
| CN105920476B (en) | Traditional Chinese medicine composition for preventing and treating Alzheimer's disease and preparation method thereof | |
| WO2002074295A1 (en) | A composition for the prophylaxis or treatment of senile dementia | |
| EP1810678A1 (en) | Use of morphine and naloxone for drug substitution | |
| CN1110313C (en) | A set of medicine for prevention and curing of cholesthiasis disease and plan for discriminating choleithiasis kind | |
| JPH0725777A (en) | Neurotrophic factor synthesis promoter | |
| KR20060130148A (en) | Use of ginkgo complexes to enhance cognitive function and reduce mental fatigue | |
| KR101401628B1 (en) | Tablet for improving hepatic function and method of manufacturing thereof | |
| DE202008007923U1 (en) | suppository | |
| KR20170062781A (en) | Composition Comprising Black Ginseng Extract having Improving Activity of Cognitive Function | |
| CN1184478C (en) | Gallstone kind identifying method and use | |
| CN100518771C (en) | Ointment for treating naevus and preparing method thereof | |
| CN1899387B (en) | Method for preventing and treating child convulsion and its preparing method | |
| CN109966278B (en) | Application of oxalylmalic acid in the preparation of drugs for the treatment of nerve cell injury | |
| CN1173355A (en) | Recovering liquid for oral cavity ulcer | |
| CN1083716A (en) | Sal ammoniac oculentum | |
| KR20110004691A (en) | Pharmaceutical composition and health food composition containing rhododendron extract having brain function improvement effect | |
| CN105663193B (en) | Rice washing water prepared pseudo-ginseng powder as well as preparation and preparation method thereof | |
| CN1053810C (en) | Compound capsule for fever release pain stop and anti-inflammation | |
| CN104258034A (en) | Traditional Chinese medicine composition for boosting immunity | |
| CN1319562C (en) | Disinfectant bactericidal Chinese medicine preparation and producing process thereof | |
| CN1201769C (en) | Medicine for treating diabetes, nephropathy | |
| CN112076323B (en) | Placebo and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |